The World Health Organization (WHO) published its first guideline for Ebola virus disease (EVD) therapeutics following a systematic review and meta-analysis of randomized clinical trials, with strong recommendations for using two monoclonal antibodies, Ebanga and Inmazeb.
The WHO stated on August 19, 2022, that EVD is a severe and too often fatal illness caused by the Ebola virus and called on the global community to increase access to these lifesaving monoclonal antibodies (mAbs) treatments.
The WHO Issues Strong Recommendations for Ebola Monoclonal Antibodies
This Mosquito-borne Viral Disease May Soon Be Prevented with an Innovative Vaccine
After many years of focused research, an innovative vaccine candidate may become available in 2023 to combat the chikungunya virus, which has spread to over 120 countries.
Chikungunya is a mosquito-borne viral disease caused by the chikungunya virus (CHIKV) transmitted to humans by a bite from Aedes mosquitoes.
The U.S. CDC says a CHIKV infection leads to symptomatic disease in 72-92% of humans after a few days.
While mortality is low, CHIKV morbidity is high.
This disease can impact over 30% of the population in areas where CHIKV is circulating.
Metformin, Ivermectin, Fluvoxamine Do Not Prevent Severe COVID-19
No difference in the primary end point seen with any of the three medications versus placebo among adults with overweight or obesity
Chronic Neuropsychiatric Symptoms Confirmed After COVID-19
Self-reported neurologic symptoms seem not to correlate with associated quantitative dysfunction